KZR vs. EGRX, CALC, ANEB, RMTI, CARM, EQ, IMMX, THTX, KRON, and AEON
Should you be buying Kezar Life Sciences stock or one of its competitors? The main competitors of Kezar Life Sciences include Eagle Pharmaceuticals (EGRX), CalciMedica (CALC), Anebulo Pharmaceuticals (ANEB), Rockwell Medical (RMTI), Carisma Therapeutics (CARM), Equillium (EQ), Immix Biopharma (IMMX), Theratechnologies (THTX), Kronos Bio (KRON), and AEON Biopharma (AEON). These companies are all part of the "pharmaceutical preparations" industry.
Kezar Life Sciences (NASDAQ:KZR) and Eagle Pharmaceuticals (NASDAQ:EGRX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, media sentiment, profitability, community ranking and analyst recommendations.
Kezar Life Sciences currently has a consensus target price of $11.00, indicating a potential upside of 1,426.93%. Eagle Pharmaceuticals has a consensus target price of $17.00, indicating a potential upside of 339.28%. Given Kezar Life Sciences' stronger consensus rating and higher probable upside, analysts clearly believe Kezar Life Sciences is more favorable than Eagle Pharmaceuticals.
Eagle Pharmaceuticals received 278 more outperform votes than Kezar Life Sciences when rated by MarketBeat users. Likewise, 70.55% of users gave Eagle Pharmaceuticals an outperform vote while only 58.01% of users gave Kezar Life Sciences an outperform vote.
67.9% of Kezar Life Sciences shares are held by institutional investors. Comparatively, 85.4% of Eagle Pharmaceuticals shares are held by institutional investors. 9.3% of Kezar Life Sciences shares are held by insiders. Comparatively, 28.9% of Eagle Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
In the previous week, Eagle Pharmaceuticals had 3 more articles in the media than Kezar Life Sciences. MarketBeat recorded 5 mentions for Eagle Pharmaceuticals and 2 mentions for Kezar Life Sciences. Kezar Life Sciences' average media sentiment score of 0.93 beat Eagle Pharmaceuticals' score of 0.87 indicating that Kezar Life Sciences is being referred to more favorably in the media.
Eagle Pharmaceuticals' return on equity of 0.00% beat Kezar Life Sciences' return on equity.
Eagle Pharmaceuticals has higher revenue and earnings than Kezar Life Sciences. Kezar Life Sciences is trading at a lower price-to-earnings ratio than Eagle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Kezar Life Sciences has a beta of 0.47, indicating that its share price is 53% less volatile than the S&P 500. Comparatively, Eagle Pharmaceuticals has a beta of 0.46, indicating that its share price is 54% less volatile than the S&P 500.
Summary
Eagle Pharmaceuticals beats Kezar Life Sciences on 11 of the 17 factors compared between the two stocks.
Get Kezar Life Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for KZR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KZR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Kezar Life Sciences Competitors List
Related Companies and Tools
